Janux Therapeutics (JANX) had the highest return between February 20, 2024 and February 28, 2024 by a small-cap US stock, returning 398.3%.
| ASSET | DATE | % RETURN |
|---|---|---|
Janux Therapeutics (JANX) | 2/20/2024 - 2/28/2024 | 398.34% |
Emergent Biosolutions (EBS) | 2/20/2024 - 2/28/2024 | 104.47% |
CytomX Therapeutics (CTMX) | 2/20/2024 - 2/28/2024 | 72.79% |
TSS, Inc Common Stock (TSSI) | 2/20/2024 - 2/28/2024 | 68.35% |
Quantum-Si (QSIAW) | 2/20/2024 - 2/28/2024 | 65% |
Acm Research (ACMR) | 2/20/2024 - 2/28/2024 | 61.47% |
Altimmune (ALT) | 2/20/2024 - 2/28/2024 | 55.69% |
Gyre Therapeutics (GYRE) | 2/20/2024 - 2/28/2024 | 55.23% |
Gaotu Techedu Inc DRC (GOTU) | 2/20/2024 - 2/28/2024 | 54.03% |
Stoke Therapeutics (STOK) | 2/20/2024 - 2/28/2024 | 52.49% |
Maravai Lifesciences Holdings (MRVI) | 2/20/2024 - 2/28/2024 | 52.47% |
Benitec Biopharma Ltd ADR (BNTC) | 2/20/2024 - 2/28/2024 | 52.03% |
GeneDx (WGS) | 2/20/2024 - 2/28/2024 | 51.96% |
Iovance Biotherapeutics (IOVA) | 2/20/2024 - 2/28/2024 | 49.61% |
Altice USA (ATUS) | 2/20/2024 - 2/28/2024 | 47.29% |
BigBearai (BBAI) | 2/20/2024 - 2/28/2024 | 44.7% |
Dogness International Corp Class A (DOGZ) | 2/20/2024 - 2/28/2024 | 42.19% |
Taysha Gene Therapies (TSHA) | 2/20/2024 - 2/28/2024 | 40.28% |
Verve Therapeutics (VERV) | 2/20/2024 - 2/28/2024 | 39.55% |
Adapthealth (AHCO) | 2/20/2024 - 2/28/2024 | 39.35% |
Bandwidth (BAND) | 2/20/2024 - 2/28/2024 | 38.86% |
Butterfly Network (BFLY) | 2/20/2024 - 2/28/2024 | 35.78% |
Celldex Therapeutics (CLDX) | 2/20/2024 - 2/28/2024 | 35.4% |
Mativ (MATV) | 2/20/2024 - 2/28/2024 | 35.1% |
Beam Therapeutics (BEAM) | 2/20/2024 - 2/28/2024 | 34.81% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
